SCHEDULE: Alafi Capital Discloses Stake in CalciMedica

Alafi Capital Company LLC and Christopher D. Alafi have reported beneficial ownership of 17.1% of CalciMedica, Inc. common stock following a recent private placement.

Summary

• Alafi Capital Company LLC and Christopher D. Alafi (collectively, the Reporting Persons) have filed a Schedule 13D, reporting beneficial ownership of 5,242,996 shares of CalciMedica, Inc. common stock, representing 17.1% of the class.
• This ownership includes 5,112,345 shares of common stock held directly and 130,651 warrants to purchase common stock at an exercise price of $7.15.
• The Reporting Persons acquired shares and warrants through various transactions, including a private placement on January 23, 2024, open market purchases in 2024 and 2025, and a significant private placement on June 25, 2026.
• In the June 25, 2026 private placement, Alafi Capital purchased 3,529,192 units for approximately $2.8 million, with each unit consisting of one share of common stock and rights to Series A and Series B warrants, subject to stockholder approval.
• The filing also details the terms of the Series A and Series B warrants, including their exercise prices, expiration dates, and beneficial ownership limitations.
• The Reporting Persons previously reported their ownership on a Schedule 13G filed on April 1, 2025, and amended on August 5, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant investment and capital raise, but also highlighting the complexities and contingencies associated with warrant exercises and regulatory approvals.

Positives

• Alafi Capital has increased its stake in CalciMedica, indicating continued confidence in the company's prospects.
• The company successfully closed a private placement on June 25, 2026, raising capital through the sale of units at $0.8033 per unit.
• The terms of the warrants provide potential for future share acquisition, contingent on certain events and approvals.

Negatives

• The significant percentage of ownership by Alafi Capital could be viewed as a concentration of influence.
• The exercise of warrants is subject to stockholder approval and beneficial ownership limitations, which could restrict the full exercise of rights.

Risks

• The exercise of Series A warrants is contingent on stockholder approval and may expire 18 months after the closing of the private placement or 30 days following the public announcement of the clearance of the Investigational New Drug Application for CM5480.
• The exercise of Series B warrants is also contingent on stockholder approval and expires five years from the closing date of the private placement.
• Beneficial ownership limitations (not to exceed 19.99%) may restrict the ability to exercise warrants for shares of common stock.
• The company's ability to register the resale of shares and warrant shares is subject to SEC review and effectiveness of registration statements.

Future Outlook

The filing details the terms and conditions of warrants, including exercise prices, expiration dates, and potential future share issuances contingent upon stockholder approval and other events. The company has also committed to filing a registration statement for the resale of shares and warrant shares within 30 days of the private placement closing.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing by Alafi Capital Company LLC indicates a significant investment and potential influence in CalciMedica, Inc. The company's recent private placement and the associated warrant structures are common strategies in the biotechnology and pharmaceutical sectors for raising capital to fund clinical trials and development, often involving specialized investment firms.

Stakeholder Impact

• Shareholders: The private placement and potential future dilution from warrant exercises could impact existing shareholders. The successful registration of shares will allow for potential resale by investors.
• Investors: The filing details the terms for new investors participating in the private placement, including the structure of units and warrants.
• Company Management: The capital raised will support ongoing operations and development, potentially impacting future strategic decisions.

Next Steps

• Stockholder approval is required for the issuance of Series A and Series B warrants and the warrant shares.
• The company must file a registration statement with the SEC within 30 days of the private placement closing to register the resale of shares and warrant shares.
• The Series A warrants will expire on the earlier of 18 months after closing or 30 days following public announcement of clearance of the Investigational New Drug Application for CM5480, or 30 days following Stockholder Approval Date if earlier.
• The Series B warrants will expire five years from the closing date of the Private Placement.

Key Dates

Recommendation

The filing indicates a significant capital raise and increased stake by a major investor, which are positive developments. However, the reliance on stockholder approval for warrant issuance and the inherent risks in clinical-stage biotechnology companies warrant a 'hold' recommendation pending further clinical trial results and regulatory progress.

Keywords

CalciMedica, Alafi Capital, Schedule 13D, Beneficial Ownership, Private Placement, Warrants, Common Stock, Christopher D. Alafi, Securities, Investment